Jon Napitupulu

LEO Pharma has announced the acceptance of its New Drug Application (NDA) by the U.S. Food and Drug Administration...

A positive efficacy, safety, and tolerability profile has emerged from Medincell and Teva’s Phase 3 SOLARIS trial evaluating Olanzapine...

Ultherapy PRIME, a groundbreaking ultrasound technology, significantly advances noninvasive skin treatments. With real-time imaging, it delivers personalized and long-lasting...

The Virtual Clinical Trials (VCT) market has surged to an estimated USD 2.64 billion in 2023, projected to reach...

AngioDynamics has initiated a comprehensive study to evaluate the efficacy and safety of the AlphaVac Mechanical Aspiration Thrombectomy System...

Takeda will showcase data from its Phase 2b trials and long-term extension study of TAK-861, an investigational orexin receptor...

Cybin Inc., a clinical-stage biotech company, is advancing its clinical programs for neuropsychiatric disorders. The company’s lead programs, CYB003...

Toronto-based Cybin Inc., a clinical-stage neuropsychiatry company focused on developing novel treatments for mental health conditions, has consolidated its...

Massive Bio, an industry leader in AI-powered clinical trial enrollment, has introduced Patient Connect, an innovative portal designed to...

The phase 3 CABINET trial evaluated cabozantinib versus placebo in patients with previously treated neuroendocrine tumors. Data from this...